Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children (LGS)

LG Chem

Status: Enrolling

Conditions: Idiopathic Short Stature; Small for Gestational Age; Chronic Renal Failure; Turner Syndrome; Growth Hormone Deficiency

Study type: Observational

Funder types: Industry

Identifiers

NCT01604395

LG-HGOS001

Details and patient eligibility

About

The purpose of this study is to evaluate the long-term safety and effectiveness of growth hormone (Eutropin Inj./Eutropin plus Inj.) treatment with GHD (Growth Hormone Deficiency), TS (Turner Syndrome),CRF (Chronic Renal Failure), SGA (Small for Gestational Age), and ISS (Idiopathic Short Stature).

Enrollment: 6,000 estimated patients

Sex: All

Ages: 2+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• short stature children aged 2 years or more
• children with GHD,TS, CRF, SGA or ISS
• written informed consent from the person, person's parent or legal guardian

Trial design

6,000 participants in 1 patient group

growth hormone